{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Alpha-Synuclein",
        "Protein_Change": {
          "ref": "Wild Type",
          "alt": "",
          "position": ""
        },
        "variant_string_id": "Alpha-Synuclein WT"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper suggests that alpha-synuclein aggregation is involved in Parkinson's disease neurotoxicity and is accelerated by the pathogenetic point mutation A30P.",
          "judgment": "Yes",
          "reasoning": "Alpha-synuclein has been linked to Parkinson's disease, and the paper explains how its aggregation can contribute to toxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses a cell phenotype rescue assay, which is a validated method to study protein function and its impact on disease.",
          "judgment": "Yes"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "sub_step_name": "3a. Basic Controls and Replicates",
              "conditions": [
                {
                  "condition_name": "Basic controls included for this assay?",
                  "met": true,
                  "info": "Wild-type protein and known loss-of-function mutant were used as controls."
                },
                {
                  "condition_name": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                  "met": true,
                  "info": "The experiments were performed in triplicate."
                }
              ]
            },
            {
              "sub_step_name": "3c. Variant Controls",
              "conditions": [
                {
                  "condition_name": "Were known pathogenic variants used as controls?",
                  "met": true,
                  "info": "Known loss-of-function mutant was used as a control."
                }
              ]
            },
            {
              "sub_step_name": "4a. Statistical Analyses",
              "conditions": [
                {
                  "condition_name": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                  "met": false,
                  "info": "No direct mention of statistical tests, p-values, effect sizes, confidence intervals, or OddsPath calculation was found."
                }
              ]
            },
            {
              "sub_step_name": "4b. No OddsPath Calculation",
              "conditions": [
                {
                  "condition_name": "How many total benign/pathogenic variant controls were used across the entire study?",
                  "info": "At least two (wild-type and loss-of-function mutant) pathogenic control variants were used."
                }
              ]
            }
          ]
        }
      ],
      "strength": "Max PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "Alpha-Synuclein",
        "Protein_Change": {
          "ref": "",
          "alt": "A30P",
          "position": "30"
        },
        "variant_string_id": "Alpha-Synuclein A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper suggests that alpha-synuclein aggregation is involved in Parkinson's disease neurotoxicity and is accelerated by the pathogenetic point mutation A30P.",
          "judgment": "Yes",
          "reasoning": "Alpha-synuclein has been linked to Parkinson's disease, and the paper explains how its aggregation can contribute to toxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses a cell phenotype rescue assay, which is a validated method to study protein function and its impact on disease.",
          "judgment": "Yes"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "sub_step_name": "3a. Basic Controls and Replicates",
              "conditions": [
                {
                  "condition_name": "Basic controls included for this assay?",
                  "met": true,
                  "info": "Wild-type protein was used as a control."
                },
                {
                  "condition_name": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                  "met": true,
                  "info": "The experiments were performed in triplicate."
                }
              ]
            },
            {
              "sub_step_name": "3c. Variant Controls",
              "conditions": [
                {
                  "condition_name": "Were known pathogenic variants used as controls?",
                  "met": false,
                  "info": "No information about using known pathogenic variants was found."
                },
                {
                  "condition_name": "Were known benign variants used as controls?",
                  "met": false,
                  "info": "No information about using known benign variants was found."
                }
              ]
            },
            {
              "sub_step_name": "4a. Statistical Analyses",
              "conditions": [
                {
                  "condition_name": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                  "met": false,
                  "info": "No direct mention of statistical tests, p-values, effect sizes, confidence intervals, or OddsPath calculation was found."
                }
              ]
            },
            {
              "sub_step_name": "4b. No OddsPath Calculation",
              "conditions": [
                {
                  "condition_name": "How many total benign/pathogenic variant controls were used across the entire study?",
                  "info": "At least two (wild-type and loss-of-function mutant) pathogenic control variants were used."
                }
              ]
            }
          ]
        }
      ],
      "strength": "Max PS3_supporting"
    }
  ]
}